Injury reactive myelin/oligodendrocyte-derived axon growth inhibition in the adult mammalian central nervous system.
Myelin inhibition is considered a constitutive, static, repulsive barrier not reactive to a central nervous system (CNS) lesion. However, recent evidence underlines the existence of considerable add-on axon growth inhibition upon CNS injury. This postlesional, reactive myelin/oligodendrocyte-derived inhibition will require the development of novel screening approaches and therapeutic reagents to promote axonal regeneration.
Schwab
Jan M
JM
CNRS UMR 7102, Equipe Développement Neuronal, Université Pierre et Marie Curie (Paris 6), Batiment B, Case 12, 9 Quai Saint Bernard, 75005 Paris, France.
Bernard
Frédéric
F
Moreau-Fauvarque
Caroline
C
Chédotal
Alain
A
D000818:Animals; D001369:Axons / Q000502:physiology*; D002493:Central Nervous System Diseases / Q000473:pathology* / Q000503:physiopathology*; D005786:Gene Expression Regulation; D008959:Models, Neurological; D009185:Myelin Proteins / Q000378:metabolism*; D018992:Myelin-Associated Glycoprotein; D009416:Nerve Regeneration; D009836:Oligodendroglia / Q000378:metabolism*; D015398:Signal Transduction
D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein